🚀 VC round data is live in beta, check it out!
Genoway Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genoway and similar public comparables like Harvard Apparatus, Bio-Works Technologies, Proteomics, AnteoTech and more.
Genoway Overview
About Genoway
Genoway SA specializes in genetic designs to serve genetically modified (GM) mice, rat and cell lines for the biopharmaceutical industries and research industries.
Founded
1999
HQ
Employees
105
Website
Sectors
Financials (LTM)
EV
$49M
Genoway Financials
Genoway reported last 12-month revenue of $25M and EBITDA of $3M.
In the same LTM period, Genoway generated $3M in EBITDA and $246K in net income.
Revenue (LTM)
Genoway P&L
In the most recent fiscal year, Genoway reported revenue of $25M and EBITDA of $6M.
Genoway expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $25M | XXX | $25M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $12M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $3M | XXX | $6M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 24% | XXX | XXX | XXX |
| EBIT Margin | 0% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $246K | XXX | $2M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | — | — | $714K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Genoway Stock Performance
Genoway has current market cap of $35M, and enterprise value of $49M.
Market Cap Evolution
Genoway's stock price is $2.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $49M | $35M | -0.6% | XXX | XXX | XXX | $0.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenoway Valuation Multiples
Genoway trades at 2.0x EV/Revenue multiple, and 14.1x EV/EBITDA.
EV / Revenue (LTM)
Genoway Financial Valuation Multiples
As of March 21, 2026, Genoway has market cap of $35M and EV of $49M.
Equity research analysts estimate Genoway's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genoway has a P/E ratio of 140.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $35M | XXX | $35M | XXX | XXX | XXX |
| EV (current) | $49M | XXX | $49M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 14.1x | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBIT | 976.9x | XXX | 30.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.0x | XXX | XXX | XXX |
| P/E | 140.5x | XXX | 16.4x | XXX | XXX | XXX |
| EV/FCF | (8.0x) | XXX | 12.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genoway Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Genoway Margins & Growth Rates
Genoway's revenue in the last 12 month grew by 20%.
Genoway's revenue per employee in the last FY averaged $0.2M.
Genoway's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genoway's rule of X is 63% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Genoway Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | (46%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Genoway Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Harvard Apparatus | XXX | XXX | XXX | XXX | XXX | XXX |
| Bio-Works Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genoway M&A Activity
Genoway acquired XXX companies to date.
Last acquisition by Genoway was on XXXXXXXX, XXXXX. Genoway acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Genoway
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGenoway Investment Activity
Genoway invested in XXX companies to date.
Genoway made its latest investment on XXXXXXXX, XXXXX. Genoway invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Genoway
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genoway
| When was Genoway founded? | Genoway was founded in 1999. |
| Where is Genoway headquartered? | Genoway is headquartered in France. |
| How many employees does Genoway have? | As of today, Genoway has over 105 employees. |
| Is Genoway publicly listed? | Yes, Genoway is a public company listed on Euronext Paris. |
| What is the stock symbol of Genoway? | Genoway trades under ALGEN ticker. |
| When did Genoway go public? | Genoway went public in 2007. |
| Who are competitors of Genoway? | Genoway main competitors are Harvard Apparatus, Bio-Works Technologies, Proteomics, AnteoTech. |
| What is the current market cap of Genoway? | Genoway's current market cap is $35M. |
| What is the current revenue of Genoway? | Genoway's last 12 months revenue is $25M. |
| What is the current revenue growth of Genoway? | Genoway revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Genoway? | Current revenue multiple of Genoway is 2.0x. |
| Is Genoway profitable? | Yes, Genoway is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Genoway? | Genoway's last 12 months EBITDA is $3M. |
| What is Genoway's EBITDA margin? | Genoway's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Genoway? | Current EBITDA multiple of Genoway is 14.1x. |
| What is the current FCF of Genoway? | Genoway's last 12 months FCF is ($6M). |
| What is Genoway's FCF margin? | Genoway's last 12 months FCF margin is (25%). |
| What is the current EV/FCF multiple of Genoway? | Current FCF multiple of Genoway is (8.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.